Jordan's Hayat Pharmaceutical Industries (HPI) recently obtained a permit from the European Union (EU) to market its products in EU countries. HPI obtained the Good Manufacturing Practices (GMP) compliance certificate pertaining to medicinal products and drugs from the EU, reported the official Xinhua news agency.
The company sent a request to the Swedish Health Authority, which inspected its facilities in Amman and was granted its GMP certificate earlier this month. A move seen as a major boost to pharmaceutical exports of the Kingdom, the permit will allow the company to market its drugs on European markets or produce drugs for any European pharmaceutical company and then export them to European markets.
Established in 1993, HPI operates out of an 8000 square meter production facility located on the outskirts of Amman. The plant produces a wide range of pharmaceutical dosage forms and has developed and registered more than 52 products on the market. HPI operates in 11 different countries throughout the Middle East and North Africa.
Pharmaceutical products are the third largest foreign currency earner for Jordan after clothing and potash exports, with the export volume rising to close to $181 million in 2001 from $154 million in the previous year. — (menareport.com)
© 2002 Mena Report (www.menareport.com)
